Journal
FRONTIERS IN ENDOCRINOLOGY
Volume 14, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fendo.2023.1124613
Keywords
diabetes; cardiomyopathy; microRNAs; long non-coding RNAs; therapeutic application
Categories
Ask authors/readers for more resources
Diabetic cardiomyopathy (DCMP) is a leading cause of morbidity and mortality in diabetic patients, and non-coding RNAs such as miRNAs and lncRNAs have been found to play a protective role in regulating processes related to DCMP. This paper reviews the literature on the roles of miRNAs and lncRNAs in DCMP in diabetes and demonstrates their potential for future DCMP treatment in diabetic patients.
Diabetes mellitus (DM) is on the rise, necessitating the development of novel therapeutic and preventive strategies to mitigate the disease's debilitating effects. Diabetic cardiomyopathy (DCMP) is among the leading causes of morbidity and mortality in diabetic patients globally. DCMP manifests as cardiomyocyte hypertrophy, apoptosis, and myocardial interstitial fibrosis before progressing to heart failure. Evidence suggests that non-coding RNAs, such as long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), regulate diabetic cardiomyopathy-related processes such as insulin resistance, cardiomyocyte apoptosis and inflammation, emphasizing their heart-protective effects. This paper reviewed the literature data from animal and human studies on the non-trivial roles of miRNAs and lncRNAs in the context of DCMP in diabetes and demonstrated their future potential in DCMP treatment in diabetic patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available